| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |